Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Peczynski

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Bone Marrow Transplantation|May 4, 2020
Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMTZinaida Peric, Myriam Labopin, Christophe Peczynski, et al.
Leukemia|June 25, 2024
How risky is a second allogeneic stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Blood Cancer Journal|March 15, 2024
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantationOlaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Leukemia|August 21, 2019
Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMTNoga Shem-Tov, Christophe Peczynski, Myriam Labopin, et al.
Bone Marrow Transplantation|May 13, 2022
Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMTIvetta Danylesko, Christophe Peczynski, Myriam Labopin, et al.
Bone Marrow Transplantation|August 19, 2025
Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working partyDrazen Pulanic, Christophe Peczynski, William Boreland, et al.
Leukemia|March 28, 2024
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Leukemia|November 1, 2024
Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemiaAvichai Shimoni, Christophe Peczynski, Myriam Labopin, et al.
Leukemia|April 17, 2025
GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working partyOlaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Bone Marrow Transplantation|August 19, 2025
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMTIvan Moiseev, Mouad Abouqateb, Christophe Peczynski, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Bone Marrow Transplantation|May 4, 2020
Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMTZinaida Peric, Myriam Labopin, Christophe Peczynski, et al.
Leukemia|June 25, 2024
How risky is a second allogeneic stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Blood Cancer Journal|March 15, 2024
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantationOlaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Leukemia|August 21, 2019
Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMTNoga Shem-Tov, Christophe Peczynski, Myriam Labopin, et al.
Bone Marrow Transplantation|May 13, 2022
Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMTIvetta Danylesko, Christophe Peczynski, Myriam Labopin, et al.
Bone Marrow Transplantation|August 19, 2025
Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working partyDrazen Pulanic, Christophe Peczynski, William Boreland, et al.
Leukemia|March 28, 2024
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Leukemia|November 1, 2024
Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemiaAvichai Shimoni, Christophe Peczynski, Myriam Labopin, et al.
Leukemia|April 17, 2025
GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working partyOlaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Bone Marrow Transplantation|August 19, 2025
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMTIvan Moiseev, Mouad Abouqateb, Christophe Peczynski, et al.
Pageof 4